6
DNKS0206.TXT

DNKS
Dankos Laboratories Tbk
Af          :
Sector Code : 53
Sector Name : PHARMACEUTICALS

(In thousand rupiah except Par Value, Closing Price and Ratios)

Financial Statement Date    : 30-Jun-2002
Fiscal Year Ends            : Dec
Months Covered in Income St : 6

Summary of Balance Sheet
  Receivables               :     198,189,668.08
  Inventories               :      86,021,070.04
  Current Assets            :     417,714,151.85
  Fixed Assets              :      93,172,358.96
  Other Asstes              :      10,938,702.62
  Total Assets              :     653,280,033.02
  Current Liabilities       :     164,128,222.88
  Longterm Liabiities       :     232,519,036.97
  Total Liabilities         :     396,647,259.85
  Authorized                :       2,550,000.00
  Paid-up Capital           :      89,302,500.00
  Par Value                 :                100
  Paid-up Capital Shares    :         893,025.00
  Retained Earnings         :     155,831,589.77
  Total Equity              :     250,564,298.71
  Minority Interest         :       6,068,474.46

Summary of Income Statement
  Total Sales               :     485,540,377.49
  Cost of Good Sold         :     252,653,982.42
  Gross Profit              :     232,886,395.07
  Operating Profit          :      91,823,515.78
  Other Income              :     -22,481,289.88
  Eearning Before Tax       :      69,342,225.90
  Tax                       :      20,119,775.85
  Net Income                :      48,713,181.05
  Closing Price             :             575.00

Per Share Data (Rp)
  Eps                       :             109.10
  Book Value                :             280.58

Financial Ratios
  Debt Equity Ratio (X)     :               1.58
  Roa (%)                   :              14.91
  Roe (%)                   :              38.88
  Npm (%)                   :              10.03
  Opm (%)                   :              18.91

Cash Flow
  CF from Operating Activities                        :      12,473,519.78
  CF from Investing Activities                        :     -18,910,354.03
  CF from Financing Activities                        :         861,404.94
  Net Increase in Cash & Cash Equivalent              :      -5,126,770.63
  Cash & Cash Equivalent at The Beginning of The Year :     106,182,383.45
  Cash & Cash Equivalent at The End of The Year       :     101,055,612.82

 
 
 
